List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 519 studies with search of: "Bayer" [Exact]
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Completed BAY43-9006 - Phase II in Advance Breast Cancer
Conditions: Cancer;   Breast Cancer
Intervention: Drug: Nexavar (Sorafenib, BAY43-9006)
2 Terminated Open-Label Trial of LEUKINE® in Active Crohn's Disease
Condition: Crohn Disease
Intervention: Drug: Sargramostim (Leukine, BAY86-5326)
3 Completed A Double-Blind "Preferred" Vardenafil Dose Study of QoL and Functional Outcomes in Males With Erectile Dysfunction
Condition: Erectile Dysfunction
Interventions: Drug: Levitra (Vardenafil, BAY38-9456);   Drug: Placebo
4 Recruiting Study of Vardenafil in Patients Suffering From Erectile Dysfunction and Metabolic Syndrome
Conditions: Erectile Dysfunction;   Metabolic Syndrome
Interventions: Drug: Levitra (Vardenafil, BAY38-9456);   Drug: Placebo
5 Completed Naproxen Sodium Extended-Release Actual Use Study
Condition: Pain
Intervention: Drug: Naproxen (BAYH6689)
6 Completed Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding
Condition: Metrorrhagia
Interventions: Drug: Qlaira (BAY86-5027, SH T00658ID);   Drug: Placebo
7 Completed BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046);   Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046);   Drug: Copaxone
8 Completed Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma
Condition: Melanoma
Interventions: Drug: MS-275 (BAY86-5274);   Drug: MS-275 (BAY86-5274)
9 Completed Investigation Into How the Body Takes up the Test Drug and Distributes it Into Various Body Organs and Tissues, How it Processes the Drug and How it Ultimately Removes it
Condition: Tumors
Intervention: Drug: SH Y03757A, (ZK 219477)
10 Completed Mirena Efficiency and Tolerability During the First Year of Use
Condition: Contraception
Intervention: Drug: Mirena (BAY86-5028)
11 Recruiting The Real-Life Efficacy and Safety of Telmisartan in Patients With Arterial Hypertension
Condition: Hypertension
Intervention: Drug: Micardis (Telmisartan, BAY68-9291)
12 Completed Trial to Evaluate Time to Symptom Relief and Elimination of Infecting Bacteria in Treating Sinusitis With Avelox
Condition: Maxillary Sinusitis
Intervention: Drug: Avelox (Moxifloxacin, BAY12-8039)
13 Completed BAY38-9456 - Pivotal Trial for Diabetes Patient
Conditions: Erectile Dysfunction;   Diabetes Mellitus
Interventions: Drug: Levitra (Vardenafil, BAY38-9456);   Drug: Levitra (Vardenafil, BAY38-9456);   Drug: Placebo
14 Suspended Inhibition of Ovulation, Patch, Ethinylestradiol and Gestodene
Conditions: Contraception;   Ovulation Inhibition
Interventions: Drug: 80876395;   Drug: 80876433
15 Completed Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
Condition: Venous Thromboembolism
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Enoxaparin
16 Active, not recruiting Safety Study of Ethinylestradiol/Drospirenone in Dysmenorrhea
Condition: Dysmenorrhea
Interventions: Drug: Ethinylestradiol / Drospirenon ( SH TO4740B;   Drug: Ethinylestradiol / Drospirenon ( SH TO4740F);   Drug: Ethinylestradiol / Drospirenon ( SH TOO186DF);   Drug: Ethinylestradiol / Drospirenon
17 Completed Phase III Study of Sorafenib in Patients With RCC
Condition: Carcinoma, Renal Cell
Intervention: Drug: Nexavar (Sorafenib, BAY43-9006)
18 Completed Evaluating the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction and Hypertension
Condition: Erectile Dysfunction
Interventions: Drug: Levitra (Vardenafil, BAY38-9456);   Drug: Placebo
19 Recruiting Prevention of Sagopilone-Induced Neurotoxicity With Acetyl-L-Carnitine (ALC)
Conditions: Prostate Cancer;   Ovarian Cancer
Interventions: Drug: Sagopilone 16 mg/m2 i.v. and Acetyl-L-Carnitine (ALC) Placebo tid;   Drug: Sagopilone 16 mg/m2 i.v. and Placebo tid
20 Recruiting Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice
Conditions: Male;   Hypogonadism
Intervention: Drug: Testosterone Undecanoate (Nebido, BAY86-5037)

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services